A trial looking at having imatinib with or without surgery for gastrointestinal stromal tumours (EORTC 62063)

Coronavirus (COVID-19)

We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.

Read about coronavirus and cancer

Cancer type:

Soft tissue sarcoma




Phase 3

This trial was looking at having surgery with imatinib for gastrointestinal stromal tumours. The trial was for gastrointestinal stromal tumours (GIST) that had spread locally or to the liver.

Doctors often treat GIST that has spread with imatinib, and it stops the cancer coming back for a while. Doctors are always looking for ways to increase the amount of time before the GIST starts to come back. They thought that having surgery, as well as imatinib may help. 

The aim of this trial was to see if adding surgery to imatinib could increase the amount of time before GIST started to come back.

Summary of results

This trial was never finished so there are no results available. The researchers were unable to recruit enough patients.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Michael Leahy

Supported by

European Organisation for Research and Treatment of Cancer (EORTC)
NIHR Clinical Research Network: Cancer

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 5589

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think